CTOs on the Move

Legacy Health System

www.legacyhealth.org

 
Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Accelerated Technologies Partners

Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jamaican Medical Cannabis Corporation

JMCC Group is the leading global provider of premium quality, sustainably grown, Jamaican medical cannabis products and related services to customers around the world, including licensed producers, medical researchers, product developers, manufacturers and distributors.

Vaxxinity

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.

Center For Innovation Inc

Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visterra Incorporated

Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza, is in a phase 2a clinical trial and expected to enter a phase 2b clinical trial by year end 2017. The company`s second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.